Researchers from Teva Pharmaceutical Industries Ltd. have presented data from preclinical studies evaluating the novel humanized human-proteinase‑activated receptor 2 (PAR2)-specific monoclonal antibody, TEV-56192, as potential treatment of skin inflammatory conditions.
MYC is a transcription factor that plays relevant roles in cellular processes such as glycolysis, development, cell differentiation or proliferation. Recent research has associated the transcriptional activity of MYC to the activation of T cells in multiple sclerosis.
Atopic dermatitis is a systemic inflammatory disorder where both innate immune cells such as dendritic cells (DCs) and adaptive immune cells, such as B and T cells, contribute to cutaneous inflammation. B and T lymphocyte attenuator (BTLA), highly expressed in mature DCs, is crucial to modulate the activity of all immune cells and acts as a co-inhibitory checkpoint receptor.
After a team at the Hospital Universitari Vall d’Hebron found that histone deacetylase 3 (HDAC3) has a role in the chronic inflammatory response in the central nervous system in models of traumatic brain injury, they investigated its role in autoimmune demyelination.
Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of patients with B-cell-driven neurologic autoimmune diseases, including multiple sclerosis and myasthenia gravis.
Researchers from Paragon Therapeutics Inc. presented the preclinical characterization of ORKA-001 (PR-035), a novel half-life extended monoclonal antibody targeting the p19 subunit of IL-23, designed to treat chronic skin disorders such as plaque psoriasis.
Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies. Satralizumab, a humanized anti-IL-6 receptor (IL-6R) antibody, has been approved for the treatment of NMOSD but the effects of IL-6R inhibition in myelitis severity have not been fully explored.
At the 2024 European College of Neuropsychopharmacology (ECNP) Congress, researchers have presented work that could lead to ways to boost brain development and prevent neurodegeneration in individuals with Down syndrome.
The differentiation of oligodendrocyte progenitor cells (OPCs) into oligodendrocytes (OLs) promotes the remyelination in human brain. In multiple sclerosis (MS), dysfunctional OPC differentiation leads to remyelination failure and subsequent severe neurological disability.
RSS
